^
3ms
PInNACLe: Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (clinicaltrials.gov)
P2, N=60, Completed, Australasian Leukaemia and Lymphoma Group | Unknown status --> Completed | N=100 --> 60
Trial completion • Enrollment change
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
imatinib • Tasigna (nilotinib) • ViraferonPeg (peginterferon-α-2b)
over1year
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma (clinicaltrials.gov)
P2, N=29, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: May 2023 --> May 2026
Trial completion date
|
temozolomide • ViraferonPeg (peginterferon-α-2b)
over1year
Trial completion • Surgery
|
cisplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • ViraferonPeg (peginterferon-α-2b)
almost2years
Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. (PubMed, Cancers (Basel))
Later, pegylated IFN-α2a (Pegasys) and pegylated IFN-α2b (PegIntron) were introduced, which have since been reported to be better tolerated due to reduced toxicity...Within the hematological malignancies, rIFN-α2 has been used off-label for decades in patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs)-i.e., essential thrombocythemia, polycythemia vera, and myelofibrosis-and in recent years rIFN-α2 has been revived with the marketing of ropeginterferon-α2b (Besremi) for the treatment of polycythemia vera patients...Another rIFN formulation-recombinant interferon-β (rIFN-β)-has been used for decades in the treatment of multiple sclerosis but has never been studied as a potential agent to be used in patients with MPNs, although several studies and reviews have repeatedly described rIFN-β as an effective anticancer agent as well. In this paper, we describe the rationales and perspectives for launching studies on the safety and efficacy of rIFN-β in patients with MPNs.
Journal
|
IFNA1 (Interferon Alpha 1) • IFNB1 (Interferon Beta 1)
|
Pegasys (pegylated interferon α -2a) • Besremi (ropeginterferon alfa-2b-njft) • ViraferonPeg (peginterferon-α-2b)
over3years
Clinical • Trial termination
|
IFNG (Interferon, gamma) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • IFNA1 (Interferon Alpha 1)
|
Actimmune (interferon gamma-1 b) • ViraferonPeg (peginterferon-α-2b)
4years
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (clinicaltrials.gov)
P1, N=18, Completed, National Cancer Institute (NCI) | Recruiting --> Completed | N=40 --> 18 | Trial completion date: Jul 2023 --> Sep 2020 | Trial primary completion date: Apr 2022 --> Sep 2020
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
IFNG (Interferon, gamma) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • IFNA1 (Interferon Alpha 1)
|
Actimmune (interferon gamma-1 b) • ViraferonPeg (peginterferon-α-2b)
almost5years
Peginterferon and TIL Therapy for Metastatic Melanoma (clinicaltrials.gov)
P1/2, N=12, Completed, Inge Marie Svane | Active, not recruiting --> Completed
Clinical • Trial completion • Combination therapy
|
IL2 (Interleukin 2)
|
fludarabine IV • Proleukin (aldesleukin) • ViraferonPeg (peginterferon-α-2b) • cyclophosphamide intravenous